| Added by | standudu |
|---|---|
| Last modified by | mollevi |
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Second-line therapy in elderly patients with advanced nonsmall cell lung cancer |
| Creator | Quoix et al. |
| Author | E. Quoix |
| Author | V. Westeel |
| Author | L. Moreau |
| Author | E. Pichon |
| Author | A. Lavole |
| Author | J. Dauba |
| Author | D. Debieuvre |
| Author | P. J. Souquet |
| Author | L. Bigay-Game |
| Author | E. Dansin |
| Author | M. Poudenx |
| Author | O. Molinier |
| Author | F. Vaylet |
| Author | D. Moro-Sibilot |
| Author | D. Herman |
| Author | H. Sennelart |
| Author | J. Tredaniel |
| Author | B. Mennecier |
| Author | F. Morin |
| Author | L. Baudrin |
| Author | B. Milleron |
| Author | G. Zalcman |
| Author | Thoracique Intergroupe Francophone de Cancerologie |
| Abstract | There is no dedicated study on second-line treatment for elderly patients with advanced nonsmall cell lung cancer (NSCLC). We report the results on second-line erlotinib therapy from our previously published phase III study comparing single-agent therapy with platinum-based doublet (carboplatin plus paclitaxel) therapy in 451 elderly patients. Erlotinib was given to patients exhibiting disease progression or experiencing excessive toxicity during first-line therapy, until further progression or unacceptable toxicity. In total, 292 (64.7%) patients received erlotinib as second-line therapy. Initial performance status 0-1, stage IV NSCLC and an Activities of Daily Living score of 6 were independent factors for receiving erlotinib. Median (95% CI) overall survival was 4 (3.2-6.7) versus 6.8 (5.0-8.3) months in the single-agent and doublet arms, respectively (p=0.089). Performance status 0-1, never having smoked, adenocarcinoma and weight loss |
| Publication | Eur Respir J |
| Volume | 43 |
| Pages | 240-9 |
| Date | Jan 2014 |
| Journal Abbr | The European respiratory journal |
| DOI | 10.1183/09031936.00048213 |
| ISSN | 1399-3003 (Electronic) 0903-1936 (Linking) |
| Tags | Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology, Cohort Studies, Disease Progression, Female, Humans, Lung Neoplasms/*drug therapy/pathology, Male, Protein Kinase Inhibitors/*therapeutic use, Quinazolines/*therapeutic use, Receptor, Epidermal Growth Factor/*antagonists & inhibitors, Treatment Failure, Treatment Outcome |
| Date Added | 2018/11/14 - 15:25:02 |
| Date Modified | 2018/11/14 - 15:25:02 |
| Notes and Attachments | (Note) (Note) 24114964 (Attachment) |
Institut de Recherche en Cancérologie de
